Eesti - eesti - Ravimiamet

norbrook laboratories limited - fiproniil - täpilahus - 402mg 4.02ml 4.02ml 8tk; 402mg 4.02ml 4.02ml 4tk; 402mg 4.02ml 4.02ml 60tk; 402mg 4.02ml 4.02ml 3tk; 402mg 4.02ml 4.02ml 24tk; 402mg 4.02ml 4.02ml 90tk; 402mg 4.02ml 4.02ml 1tk; 402mg 4.02ml 4.02ml 30tk; 402mg 4.02ml 4.02ml 6tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - fiproniil - täpilahus - 134mg 1.34ml 1.34ml 12tk; 134mg 1.34ml 1.34ml 4tk; 134mg 1.34ml 1.34ml 120tk; 134mg 1.34ml 1.34ml 90tk; 134mg 1.34ml 1.34ml 2tk; 134mg 1.34ml 1.34ml 1tk; 134mg 1.34ml 1.34ml 6tk; 134mg 1.34ml 1.34ml 150tk; 134mg 1.34ml 1.34ml 30tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - fiproniil - täpilahus - 67mg 0.67ml 0.67ml 2tk; 67mg 0.67ml 0.67ml 6tk; 67mg 0.67ml 0.67ml 60tk; 67mg 0.67ml 0.67ml 90tk; 67mg 0.67ml 0.67ml 1tk; 67mg 0.67ml 0.67ml 24tk; 67mg 0.67ml 0.67ml 3tk; 67mg 0.67ml 0.67ml 30tk; 67mg 0.67ml 0.67ml 120tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - fiproniil - täpilahus - 50mg 0.5ml 0.5ml 2tk; 50mg 0.5ml 0.5ml 4tk; 50mg 0.5ml 0.5ml 12tk; 50mg 0.5ml 0.5ml 6tk; 50mg 0.5ml 0.5ml 150tk; 50mg 0.5ml 0.5ml 60tk; 50mg 0.5ml 0.5ml 8tk; 50mg 0.5ml 0.5ml 3tk; 50mg 0.5ml 0.5ml 90tk; 50mg 0.5ml 0.5ml 120tk; 50mg 0.5ml 0.5ml 1tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - fiproniil - täpilahus - 268mg 2.68ml 2.68ml 3tk; 268mg 2.68ml 2.68ml 4tk; 268mg 2.68ml 2.68ml 60tk; 268mg 2.68ml 2.68ml 150tk; 268mg 2.68ml 2.68ml 6tk; 268mg 2.68ml 2.68ml 120tk; 268mg 2.68ml 2.68ml 24tk; 268mg 2.68ml 2.68ml 90tk; 268mg 2.68ml 2.68ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

virbac s.a. - kasside päritolu rekombinantne oomega interferoon - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. fiv-i nakatunud kassides oli suremus madal (5%) ja ravi ei mõjutanud.

Euroopa Liit - eesti - EMA (European Medicines Agency)

nova laboratories ireland limited - 6-merkaptopuriini monohüdraat - leukeemia, lümfoid - antineoplastilised ained - xalupriin on näidustatud ägeda lümfoblastilise leukeemia (all) raviks täiskasvanutel, noorukitel ja lastel.

Eesti - eesti - Ravimiamet

b. braun melsungen ag - kombinatsioonid - infusiooniemulsioon - 1250ml 5tk; 2500ml 5tk; 1875ml 5tk

Eesti - eesti - Ravimiamet

b. braun melsungen ag - kombinatsioonid - infusiooniemulsioon - 1875ml 5tk; 1250ml 5tk

Eesti - eesti - Ravimiamet

b. braun melsungen ag - kombinatsioonid - infusiooniemulsioon - 625ml 5tk; 1875ml 5tk; 1250ml 5tk